TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02080468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lomitapide
Description: 20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lomitapide
Description: 20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EE/norgestimate
Description: 1x0.035-mg EE/0.25-mg norgestimate tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EE/norgestimate
Description: 1x0.035-mg EE/0.25-mg norgestimate tablet
Study: NCT02386995

Intervention type: DEVICE
Intervention: BIS monitor
Description: Both types of depth of anesthesia monitoring (BIS and entropy- electrodes) are applied on patients together with standard monitoring (heart rate, blood pressure, respiratory rate). The two different types of depth of anesthesia monitoring are then compared.

Intervention type: DEVICE
Intervention: Entropy monitor
Description: Both types of depth of anesthesia monitoring (BIS and entropy- electrodes) are applied on patients together with standard monitoring (heart rate, blood pressure, respiratory rate). The two different types of depth of anesthesia
Study: NCT00279201

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine
Description: Subcutaneous injection daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine
Description: Subcutaneous injection daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine
Description: Subcutaneous injection daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lispro Low Mix
Description: Subcutaneous injection twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lispro Low Mix
Description: Subcutaneous injection twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lispro Mid Mix
Description: Lispro Mid Mix subcutaneous injection 3 times daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lispro
Description: Lispro subcutaneous injection 3 times daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lispro
Description: Lispro subcutaneous injection 3 times daily.
Study: NCT01345721

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM
Study: NCT01717781

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thunderbeat technology

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard bipolar electrosurgery
Study: NCT03917667

Intervention type: DIAGNOSTIC_TEST
Intervention: EWGSOP2
Description: EWGSOP2 criteria (Writing Group for the European Working Group on Sarcopenia in Older People 2) will be followed to determine the diagnosis of sarcopenia, considered as a dichotomous variable -yes/no- in presence of low grip strength + low muscle mass + low gait speed.
Study: NCT02585882

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluoride table salt
Study: NCT02593981

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fruit/Honey drink
Description: 2 canisters of powder containing fruit/honey mix to be mixed with water and ingested twice a day for 28 days
Study: NCT03766867

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo infusion
Description: concentrate for solution for infusion, 25 mL administered in 250 mL saline over 2 hours as single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets
Description: oral administration once daily
Study: NCT04143841

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Viveye OMNS treatment
Description: The Viveye OMNS treatment ( \~30 min) will be applied once, during the treatment visit only

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Viveye OMNS sham treatment
Description: The Viveye OMNS sham treatment ( \~30 min) will be applied once, during the treatment visit only
Study: NCT02535104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranpirnase
Description: Topical application by subject

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle control
Study: NCT02297022

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: Deep Brain Stimulation hypothalamic surgery in patients with Prader-Willi syndrome
Study: NCT02593981

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 canisters of Placebo powder containing non-active ingredient to be mixed with water and ingested twice a day for 28 days
Study: NCT03118739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verinurad 9 mg+Febuxostat 80 mg
Description: Capsule administered orally, once daily for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule administered orally, once daily for 24 weeks
Study: NCT01054768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alpha-lipoic acid and acetyl-L-carnitine
Description: none to report

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: none to report
Study: NCT03959462

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real anodal transcranial direct current stimulation
Description: A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham transcranial direct current stimulation
Description: A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used.
Study: NCT01232608

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 12 months of exercise training
Study: NCT02470546

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 1000mg twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1000mg twice a day
Study: NCT03610087

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Low Intensity Intervention
Description: Participants will have access via the online platform to the NAVIGATE self-help modules for physical activity, nutrition and quitting smoking with a list of community resources. Subjects will be sent a standard reminder emails once per week to complete their modules and connect with their main provider for any assistance.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Intervention
Description: Participants will receive individualized treatment planning, in collaboration with a Care Coordinator, and the Virtual Care Team (VCT). Interactive modules on physical activity, nutrition and quitting smoking will be provided via the online platform. the virtual team will be engaged to provide treatment and/or recommendations regarding the following: increasing physical activity, improving nutrition and diet, smoking cessation (psychosocial support plus medications), and medication adherence. Participants in this arm will have weekly check-ins with their assigned Care Coordinator where they will be able to discuss VCT recommendations, and progress on their goals.
Study: NCT01172769

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: After dissolving and dilution 25 mg of temsirolimus will be administered i.v. once a week by 30 minute infusion.~Study treatment will continue until tumor progression or unless unacceptable toxicity is encountered.
Study: NCT02908373

Intervention type: OTHER
Intervention: Implementation of the coaching model
Description: 20 hours methodological help for each nursing home and an implementation kit

Intervention type: OTHER
Intervention: Implementation of the coaching model
Description: 20 hours methodological help for each nursing home and an implementation kit
Study: NCT04511754

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experiential Psychotherapy Skill Training
Description: The Experiential Training intervention will include components of training not usually included in standard clinical training experiences; such components include opportunities for deliberate practice of the skills trained, live supervision and feedback, and discussion with a trainer focused on the skills taught and the trainees' performance.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Psychotherapy Skill Training
Description: Standard didactic training with research support, examples, and opportunities to ask questions.
Study: NCT03389542

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Early mitral valve repair

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical interview and echocardiography
Description: Clinical interview and echocardiography every 6 months.
Study: NCT00511875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxycycline monohydrate
Description: 50mg once daily for 24 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo taken once daily for 24 months
Study: NCT03475732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XueBiJing injection
Description: 100mL XueBiJing injection (dissolved with 100 mL of 0.9% normal saline),intravenous infusion for 1.25 h, q12h for 5 days
Study: NCT00990080

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pediacel® and Infanrix™-IPV/Hib
Description: 0.5 mL IM at 2,4 and 6 months of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pediacel® and Infanrix™-IPV/Hib
Description: 0.5 mL IM at 2,4 and 6 months of age
Study: NCT02616887

Intervention type: RADIATION
Intervention: Single dose SBRT and VMAT technique
Description: One fraction of 18 Gy delivered in one day with VMAT and Flattening filter-free (FFF) beams.
Study: NCT00784394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diindolylmethane
Description: Given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies
Study: NCT03993548

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Element 1 - Exercise
Description: Daily wellness element focusing on Exercise; adherence documented online daily

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Element 2 - Mindfulness
Description: Daily wellness element focusing on Mindfulness Meditation; adherence documented online daily

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Element 3 - Sleep Hygiene
Description: Daily wellness element focusing on sleep hygiene; adherence documented online daily

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Element 4 - Social Connectedness
Description: Daily wellness element focusing on Social Connectedness; adherence documented online daily

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Element 5 - Nutrition
Description: Daily wellness element focusing on Nutrition; adherence documented online daily

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Element 6 - Wellness Exercises
Description: Daily wellness workbook exercises focusing on improving mental wellness; adherence documented online daily

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Element 7 - Motivational Messages
Description: Daily motivational emails offering information on one of the 5 wellness elements each day (Exercise, Mindfulness Meditation, Sleep, Social Connectedness, and Nutrition)
Study: NCT01723722

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: Concentration is 1mg/mL administered every 12 hours given on sliding scale in response to last NAS score.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diluted Deodorized Tincture of Opium
Description: Concentration is 1:24 dilution for a concentration of 0.4%
Study: NCT00033358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: medroxyprogesterone
Description: Given intramuscularly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ethinyl estradiol
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: norgestrel
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02354664

Intervention type: OTHER
Intervention: Thoracic MRI
Description: Imaging of the diaphragm will be completed during resting breathing, and then during a maximal voluntary ventilation maneuver.

Intervention type: OTHER
Intervention: Thoracic MRI
Description: Imaging of the diaphragm will be completed during resting breathing, and then during a maximal voluntary ventilation maneuver.

Intervention type: OTHER
Intervention: Spirometry
Description: Upright forced vital capacity (FVC)

Intervention type: OTHER
Intervention: Spirometry
Description: Upright forced vital capacity (FVC)

Intervention type: OTHER
Intervention: Inspiratory Load Compensation
Description: A spring-loaded pressure device will resist inspiration. The patient must generate the threshold inspiratory pressure to receive airflow. The changes in breathing timing, flow and volume will be recorded.

Intervention type: OTHER
Intervention: Inspiratory Load Compensation
Description: A spring-loaded pressure device will resist inspiration. The patient must generate the threshold inspiratory pressure to receive airflow. The changes in breathing timing, flow and volume will be recorded.

Intervention type: OTHER
Intervention: Maximal Inspiratory Pressure
Description: Measure the maximal airflow on inhalation

Intervention type: OTHER
Intervention: Maximal Inspiratory Pressure
Description: Measure the maximal airflow on inhalation

Intervention type: OTHER
Intervention: Resting Breathing Pattern
Description: The breathing pattern will be assessed when the subject is seated and in a relaxed state.

Intervention type: OTHER
Intervention: Resting Breathing Pattern
Description: The breathing pattern will be assessed when the subject is seated and in a relaxed state.

Intervention type: OTHER
Intervention: Respiratory Muscle Endurance Test
Description: Evaluates the time limit that a participant can maintain ventilation while breathing with a submaximal inspiratory threshold load.
Study: NCT02078440

Intervention type: DRUG
Group type: OTHER
Intervention: Bromocriptine mesylate
Description: Cycloset (bromocriptine mesylate quick release) 0.8 mg tablets, weight adjusted 1.6 mg- 4.8 mg
Study: NCT02354664

Intervention type: OTHER
Intervention: Respiratory Muscle Endurance Test
Description: Evaluates the time limit that a participant can maintain ventilation while breathing with a submaximal inspiratory threshold load.
Study: NCT04648540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 mic/kg/h
Description: In Group I (OFA) the following drugs will be administered preoperatively:~Acetaminophen 1 gm and Ketorolac 30 mg in 100 mL i.v. over 10 minutes Dexmedetomidine loading dose of 0.5 mic/kg i.v. over 10 minutes Lidocaine loading dose of 1.5 mg/kg i.v. over 10 minutes~The following drugs will be administered as a continuous infusion throughout the operation:~* Dexmedetomidine 0.5 mic/kg/h~* Lidocaine 0.5 mg/kg/h~The following drugs will be administered postoperatively:~Acetaminophen 1 gm/6h ketorolac 30 mg/8h Pregabalin 150 mg once at night Celecoxib 200 mg/24 hours
Study: NCT00906347

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 75 micrograms orally every 4 hours for up to 2 doses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Intravenous oxytocin will be administered per the established Labor and Delivery protocol at Parkland Memorial Hospital
Study: NCT04354194

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Physiotherapy
Description: Conventional Physiotherapy consist of Hotpacks, TENS and US.The participants were positioned in sitting and supported with a pillow under the head, 20 min hot pack was applied. Therapatic Ultrason were applied with the frequency of 1 MHz, intensity of 1,5 watt/cm² and duration of 5 minute. TENS was applied to the cervical region with 2-channel, 4 surface electrodes at 60-120 Hz, and 50-100 pulse duration for 20 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopathic Manupilative Treatment
Description: Osteopathic Manupilative Treatment consist of stretching the fascia to the cervical region, soft tissue mobilization to the surrounding muscles, cervical manual traction, passive joint mobilization to the 7 cervical spine, passive joint mobilization to the 1st costa, passive joint mobilization to the clavicle and passive joint mobilization to the sternum mobilization in supine and prome positions.
Study: NCT03618979

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PPP treatment
Description: The day prior to or the morning of the procedure, patient will have their blood drawn by a phlebotomist and processed into 5 or 10 cc of PPP depending on if there is lumbar multifidus atrophy in one or two levels. Using sterile technique and ultrasound guidance, once touching the lamina the physician will inject 2.5 cc of PPP. The physician will then repeat the procedure on the opposite side.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP treatment
Description: The day prior to or the morning of the procedure, patient will have their blood drawn by a phlebotomist and processed into 5 or 10 cc of 5x PRP depending on if there is lumbar multifidus atrophy in one or two levels. Using sterile technique and ultrasound guidance, once touching the lamina the physician will inject 2.5 cc of PRP and remove the needle. The physician will then repeat the procedure on the opposite side and at the next level if indicated.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP and PL Combo treatment
Description: The day prior to or the morning of the procedure patient will have their blood drawn by a phlebotomist and processed into 5 or 10 cc of 5x PRP and 5 or 10 cc of PL and 2 or 4 cc of 14x PRP depending on if there will be one or two levels injected. Using sterile technique, under ultrasound visualization into the lumbar multifidus and onto the lamina, the physician will inject the PRP and remove the needle. Under intermittent x-ray, epidural flow is confirmed with contrast, the physician will inject 2cc of the PL and 1cc of 0.5% ropivacaine into the epidural space. Once flow is confirmed for the epidural injection and facet with contrast, 1cc of the 14x PRP is injected into the facet joint. Procedure repeated on the opposite side and next level if indicated.
Study: NCT03917628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCT630
Description: SCT630 single s.c. injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab-EU source
Description: adalimumab-EU source single s.c. injection
Study: NCT02646345

Intervention type: PROCEDURE
Intervention: Surgical checklist
Description: Use of the World Health Organization Surgical checklist
Study: NCT02217722

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ulcerative Colitis Diet
Description: we have postulated that a diet that increases butyrate through fiber exposure, reduces intestinal sulfur exposure, and increases vitamin D levels could be beneficial for patients with Ulcerative Colitis. To date, no study has explored this possibility.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic cocktail
Description: We have postulating that antibiotic therapy can alter the microbiota clinically. Controlling the microbiota by antibiotics may allow for control of the disease without immune suppression
Study: NCT02717221

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 18F-MPG
Description: N-(3-chloro-4-fluorophenyl)-7-(2-(2-(2-(2-\[18F\] fluoroethoxy) ethoxy) ethoxy) ethoxy)-6-methoxyquinazolin-4-amine (18F-MPG)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 18F-MPG
Description: N-(3-chloro-4-fluorophenyl)-7-(2-(2-(2-(2-\[18F\] fluoroethoxy) ethoxy) ethoxy) ethoxy)-6-methoxyquinazolin-4-amine (18F-MPG)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 18F-MPG
Description: N-(3-chloro-4-fluorophenyl)-7-(2-(2-(2-(2-\[18F\] fluoroethoxy) ethoxy) ethoxy) ethoxy)-6-methoxyquinazolin-4-amine (18F-MPG)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 18F-MPG
Description: N-(3-chloro-4-fluorophenyl)-7-(2-(2-(2-(2-\[18F\] fluoroethoxy) ethoxy) ethoxy) ethoxy)-6-methoxyquinazolin-4-amine (18F-MPG)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 18F-MPG
Description: N-(3-chloro-4-fluorophenyl)-7-(2-(2-(2-(2-\[18F\] fluoroethoxy) ethoxy) ethoxy) ethoxy)-6-methoxyquinazolin-4-amine (18F-MPG)
Study: NCT03113942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide 2 MG Oral Capsule [Pomalyst]
Description: Pomalidomide is an oral immunomodulatory derivative of thalidomide. Thalidomide and its derivatives are small molecules with broad effects on immune activation, including T-cell activation and responsiveness. Pomalidomide augments T cell responsiveness and proliferation by several mechanisms, many mediated by transcriptional regulation downstream of its primary target, cereblon. Effects include increased production of IL-2 and interferon-γ (IFN-γ), enhanced CD4+ and CD8+ T cell co-stimulation.
Study: NCT03312387

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Aerobic exercise performed 3/d per week during intervention

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: Aerobic exercise performed 3/d per week during intervention

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Essential Amino Acids
Description: Mixture of 10g of essential amino acids ingested throughout intervention

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10g of maltodextrin ingested throughout intervention
Study: NCT04348383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defibrotide
Description: 6.25 mg/kg every 6 hours in 2 hours infusion for 7 or 15 days
Study: NCT02717221

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 18F-MPG
Description: N-(3-chloro-4-fluorophenyl)-7-(2-(2-(2-(2-\[18F\] fluoroethoxy) ethoxy) ethoxy) ethoxy)-6-methoxyquinazolin-4-amine (18F-MPG)